Ron Lahav

Ron Lahav has a diverse work experience in the biotechnology industry. Ron is currently the Managing Director at NIBN, where they oversee the operations of the organization. Prior to that, they co-founded AltA-ZuZ Therapeutics, a company focused on developing a novel inhibitor for autoimmune diseases. Ron also served as the Executive Director of Research and Development at NIBN, where they managed multiple research projects and scientists in various fields. Ron has held leadership roles at SpliSense, ART BioScience Ltd, and Quiet Therapeutics, where they played a crucial role in the development and commercialization of therapeutics. Ron has also worked at Quark Pharmaceuticals, AnorMED, and Princeton University in earlier stages of their career.

Ron Lahav earned their PhD in Environmental Microbiology from Ben Gurion University of the Negev from 1997 to 2002. Following that, they pursued a post-doctorate in Molecular Biology at Princeton University from 2002 to 2005.